WallStreetZenWallStreetZen

NASDAQ: HOWL
Werewolf Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for HOWL

Based on 3 analysts offering 12 month price targets for Werewolf Therapeutics Inc.
Min Forecast
$8.30+145.56%
Avg Forecast
$11.10+228.4%
Max Forecast
$15.00+343.79%

Should I buy or sell HOWL stock?

Based on 3 analysts offering ratings for Werewolf Therapeutics Inc.
Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their HOWL stock forecasts and price targets.

HOWL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
EF Hutton
Top 16%
85
Strong BuyAssumes$8.30+145.56%2023-05-25
Bank of America
Bottom 17%
17
Strong BuyMaintains$10.00+195.86%2023-05-12
HC Wainwright & Co.
Bottom 20%
20
BuyReiterates$15.00+343.79%2023-05-11

1 of 1

Forecast return on equity

Is HOWL forecast to generate an efficient return?
Company
-95.59%
Industry
29.69%
Market
89.37%
HOWL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is HOWL forecast to generate an efficient return on assets?
Company
-59.33%
Industry
11.82%
HOWL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

HOWL revenue growth forecast

How is HOWL forecast to perform vs Biotechnology companies and vs the US market?
Company
71.75%
Industry
64.21%
Market
8.83%
HOWL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
HOWL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

HOWL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
HOWL$3.38$11.10+228.40%Strong Buy
LIFE$2.20$19.00+763.64%Strong Buy
STTK$2.86$21.00+634.27%Buy
CDXC$1.59$5.00+214.47%Buy
CAPR$4.70$18.00+282.98%Buy
View Top Biotech Stocks

Werewolf Therapeutics Stock Forecast FAQ

Is Werewolf Therapeutics Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: HOWL) stock is to Strong Buy HOWL stock.

Out of 3 analysts, 2 (66.67%) are recommending HOWL as a Strong Buy, 1 (33.33%) are recommending HOWL as a Buy, 0 (0%) are recommending HOWL as a Hold, 0 (0%) are recommending HOWL as a Sell, and 0 (0%) are recommending HOWL as a Strong Sell.

If you're new to stock investing, here's how to buy Werewolf Therapeutics stock.

What is HOWL's forecast return on equity (ROE) for 2023-2025?

(NASDAQ: HOWL) forecast ROE is -95.59%, which is considered weak.

What is HOWL's Price Target?

According to 3 Wall Street analysts that have issued a 1 year HOWL price target, the average HOWL price target is $11.10, with the highest HOWL stock price forecast at $15.00 and the lowest HOWL stock price forecast at $8.30.

On average, Wall Street analysts predict that Werewolf Therapeutics's share price could reach $11.10 by May 25, 2024. The average Werewolf Therapeutics stock price prediction forecasts a potential upside of 228.4% from the current HOWL share price of $3.38.

What is HOWL's forecast return on assets (ROA) for 2023-2025?

(NASDAQ: HOWL) forecast ROA is -59.33%, which is lower than the forecast US Biotechnology industry average of 11.82%.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.